New insider activity at Quanterix ( (QTRX) ) has taken place on September 17, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a notable move, CFO Vandana Sriram has acquired 4,150 shares of Quanterix stock, with the transaction valued at $19,878. This purchase reflects a significant investment in the company’s future by its financial leader.
Recent Updates on QTRX stock
In recent developments, Quanterix’s stock has been influenced by the Centers for Medicare & Medicaid Services (CMS) releasing a preliminary determination for the clinical lab fee schedule, which included pricing Quanterix’s LucentAD Complete test at $897. This pricing is seen as a positive development for Quanterix, as it could lead to increased average selling prices if the company achieves Advanced Diagnostic Laboratory Test (ADLT) status. Despite this, the stock was downgraded to a Hold rating by Canaccord, reflecting a cautious stance amid strategic gains and financial hurdles. The market’s reaction to these announcements has been mixed, balancing the potential for growth with existing challenges.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score reflects significant financial challenges, including declining revenues and negative cash flow, which are the most impactful factors. While strategic initiatives and corporate events offer potential for future growth, current financial and technical indicators suggest caution.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
YTD Price Performance: -53.81%
Average Trading Volume: 733,482
Technical Sentiment Signal: Sell
Current Market Cap: $230.9M